Vizsgálati helyszín
Florida Cancer Specialists - North
St. Petersburg, Florida 33705, Egyesült ÁllamokMég nincs intézményhez kötve
- 15futó vizsgálat
- 11lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 26 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis13 vizsgálat
- 2. fázis9 vizsgálat
- 2/3. fázis3 vizsgálat
- 1/2. fázis1 vizsgálat
- Állapot
- Toboroz10 vizsgálat
- Lezárult8 vizsgálat
- Fut, nem toboroz5 vizsgálat
- Visszavonták2 vizsgálat
- Leállították1 vizsgálat
- Fő szponzor
- Bristol-Myers Squibb4 vizsgálat
- Novartis Pharmaceuticals3 vizsgálat
- Daiichi Sankyo2 vizsgálat
- Eli Lilly and Company2 vizsgálat
- SCRI Development Innovations, LLC2 vizsgálat
- és még 13
Futó vizsgálatok
Toboroz
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07562152· 3. fázis· Immuneering Corporation· Forrás
Contact: Study Team
Toboroz
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
NCT07357727· 3. fázis· Novartis Pharmaceuticals· Forrás
Contact: Kelly Whitehead
Toboroz
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
NCT07221149· 2/3. fázis· Bristol-Myers Squibb· Forrás
Contact: Muhammad Imam, Site 0430
Toboroz
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
NCT07221357· 2/3. fázis· Bristol-Myers Squibb· Forrás
Contact: Maen Hussein, Site 0575
Toboroz
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
NCT07218146· 3. fázis· Zai Lab (Shanghai) Co., Ltd.· Forrás
Toboroz
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
NCT07173751· 3. fázis· BioNTech SE· Forrás
Toboroz
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
NCT06890598· 3. fázis· Eli Lilly and Company· Forrás
Contact: Ernesto Bustinza-Linares (principal investigator)
Toboroz
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
NCT06646276· 3. fázis· Bristol-Myers Squibb· Forrás
Contact: Maen Hussein, Site 0020
Toboroz
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
NCT06463028· 2. fázis· Faeth Therapeutics· Forrás
Contact: Medical Monitor
Toboroz
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
NCT06561386· 3. fázis· Bristol-Myers Squibb· Forrás
Contact: Mamta Choksi, Site 0358
Fut, nem toboroz
Phase III Study of AK112 for NSCLC Patients
NCT06396065· 3. fázis· Summit Therapeutics· Forrás
Fut, nem toboroz
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
NCT05555732· 3. fázis· Daiichi Sankyo· Forrás
Fut, nem toboroz
Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia
NCT05384587· 2. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
9-ING-41 in Patients With Advanced Cancers
NCT03678883· 2. fázis· Actuate Therapeutics Inc.· Forrás
Fut, nem toboroz
A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer
NCT02107703· 3. fázis· Eli Lilly and Company· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Lezárt vizsgálatok
Visszavonták
Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer
NCT07353957· 2. fázis· Genmab· Forrás
Toboroz
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
NCT06695845· 2. fázis· Jazz Pharmaceuticals· Forrás
Contact: Clinical Trial Disclosure & Transparency
Lezárult
Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)
NCT05153239· 3. fázis· PharmaMar· Forrás
Lezárult
Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
NCT05103358· 2. fázis· Aadi Bioscience, Inc.· Forrás
Leállították
Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab
NCT04887831· 2. fázis· G1 Therapeutics, Inc.· Forrás
Lezárult
Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation
NCT04666259· 3. fázis· Novartis Pharmaceuticals· Forrás
Lezárult
A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer
NCT04699630· 2. fázis· SCRI Development Innovations, LLC· Forrás
Lezárult
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer
NCT04381832· 1/2. fázis· Arcus Biosciences, Inc.· Forrás
Lezárult
Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer
NCT04082364· 2/3. fázis· MacroGenics· Forrás
Lezárult
Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor
NCT03977467· 2. fázis· SCRI Development Innovations, LLC· Forrás
Lezárult
DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]
NCT03529110· 3. fázis· Daiichi Sankyo· Forrás
Hibát jelzek